The association of nutritional and inflammatory biomarkers with overall survival in patients with non‐small‐cell lung cancer treated with immune checkpoint inhibitors
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von I M Horstman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Horizon 2020 Framework Programme.
Abstract (Originalsprache)
Objectives
Pretreatment biomarkers are needed to identify patients with non‐small‐cell lung cancer (NSCLC) likely to have worse survival. This ensures that only patients with a real chance of benefit receive immune checkpoint inhibitor (ICI) treatment. In this study, we examined the associations of baseline nutritional and inflammatory biomarkers with overall survival in a real‐world cohort of NSCLC patients who received ICIs. Materials and Methods We used prospectively collected data from the OncoLifeS data biobank. The cohort included 500 advanced‐stage NSCLC patients treated with ICIs from May 2015 to June 2021. Biomarkers were evaluated within 2 weeks before ICI treatment: neutrophil‐to‐lymphocyte ratio, C‐reactive protein (CRP), Glasgow prognostic score, CRP/albumin ratio (CAR), prognostic nutritional index (PNI), and advanced lung cancer inflammation index. For each biomarker, low‐ and high‐risk groups were defined using literature‐based cut‐offs. Adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs) were estimated using adjusted survival analysis.
Results
Most patients were male (60.8%), the mean baseline age was 65 ± 9 years, and 88% had stage IV disease. For each biomarker, low‐risk patients had better overall survival (all, p < 0.001), with CAR and PNI showing the strongest associations. In multivariable analyses a combined CAR/PNI risk score had a stronger association with overall survival (aHR 3.09, 95% CI 2.36–4.06) than CAR alone (aHR 2.22, 95% CI 1.79–2.76) or PNI alone (aHR 2.09, 95% CI 1.66–2.61).
Conclusion
These results highlight the potential value of nutritional and inflammatory biomarkers, in particular CAR and PNI, in identifying NSCLC patients with highest mortality risk before starting ICI treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Pulmonology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
ORCID-Profile: I M Horstman, G H de Bock
Förderung
- Horizon 2020 Framework Programme
Zitieren
APA
Horstman, I. M., Vinke, P. C., Suazo-Zepeda, E., Hiltermann, T. J. N., Heuvelmans, M. A., Corpeleijn, E., & de Bock, G. H. (2024). The association of nutritional and inflammatory biomarkers with overall survival in patients with non‐small‐cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15401
Vancouver
Horstman IM, Vinke PC, Suazo-Zepeda E, Hiltermann TJN, Heuvelmans MA, Corpeleijn E, et al. The association of nutritional and inflammatory biomarkers with overall survival in patients with non‐small‐cell lung cancer treated with immune checkpoint inhibitors. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15401
BibTeX
@article{Horstman2024,
author = {Horstman, I M and Vinke, P C and Suazo-Zepeda, E and Hiltermann, T J N and Heuvelmans, M A and Corpeleijn, E and de Bock, G H},
title = {The association of nutritional and inflammatory biomarkers with overall survival in patients with non‐small‐cell lung cancer treated with immune checkpoint inhibitors},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15401}
}
EUVIMED